MURATA-MANUFACTURING
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has announced its new Parasitic Element Coupling Device. This state-of-the-art solution improves antenna efficiency by magnetically coupling the parasitic element with the antenna and is the world's first solution designed for Wi-Fi 6E and Wi-Fi 7 products. For designers of smartphones, tablets, network routers, game consoles, and other compact electronics, it enables them to build more efficient antennas – a key requirement for many modern space-constrained devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206488044/en/
[Murata Manufacturing Co., Ltd.] Parasitic element coupling device (Photo: Business Wire)
To develop products conforming to Wi-Fi 6E and Wi-Fi 7 standards, which utilize high-speed wireless communication, multiple high-performance antennas must be installed in electronic devices to improve communication speed and quality. However, as the dimensions of heatsinks and batteries expand, as processors become more advanced, the available space for mounting antennas tends to decrease.
Consequently, there is a need for smaller antennas. But there is a technical limitation, in that the efficiency of wide-band antennas decreases when they are miniaturized. Therefore, designers need a solution that achieves both miniaturization and high performance.
Murata’s solution is a parasitic element coupling device, made with its multilayer technology as a four-terminal surface-mount component of just 1.0 x 0.5 x 0.35mm.
Murata’s parasitic element coupling device connects the feeding antenna* to its parasitic elements more effectively than is possible through free space. It acts as a tiny coupling device whose compact size enables strong coupling performance without the use of magnetic materials, which would be inappropriate at the targeted operating frequencies. One side of the coupling device is connected, at very low insertion loss, between a device’s RF circuitry and its main antenna. The other side is connected between the ground and the parasitic element. The resultant, more direct coupling enables the resonance characteristics of the parasitic element to be added to those of the feeding antenna. As a result, it enables more efficient operation across a broader frequency range or on multiple discrete bands.
The device helps to combat that when an antenna is made smaller, the coupling between it and the parasitic elements is reduced, while the coupling between the parasitic elements and the ground is increased. By sustaining the coupling between the feeding antenna and parasitic element, parasitic element coupling device enables designers to use miniaturized antenna design methods without impacting the communication band of efficiency.
The feeding antenna can cause an impedance mismatch when used over a wide band, leading to a degradation in wireless performance. In addition, when an antenna with a mismatched impedance is connected to a communication circuit using a long cable, the long cable can promote the impedance mismatch, causing larger insertion loss than expected and significantly reducing wireless communication performance. By using the device, you can improve antenna matching and reduce performance degradation in wireless communications even when using long cables.
You can see more information about Murata’s parasitic element coupling device by going to: LINK
Please contact us for details: contact form
Editor’s note:
*An antenna connected to RF module with cable, etc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231206488044/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pace selected by Prudential Financial to help automate its insurance operations with agentic AI4.12.2025 14:15:00 CET | Press release
Pace’s AI-powered agents are helping to streamline policy service and perform other quality assurance tasks within Prudential’s Individual Life Insurance business Pace, the agentic workforce for insurance, was chosen by Prudential’s Individual Life Insurance (ILI) business to help simplify and improve its service delivery. Pace’s AI-powered agents are now streamlining policy servicing and supporting quality assurance efforts within Prudential’s ILI business. The first set of automated systems is now live taking on thousands of hours of work. “Our work with Prudential is an example of how AI can be used as a strategic advantage,” said Pace CEO Jamie Cuffe. “We’re thrilled to support their exceptional team with AI agents in production today that deliver best-in-class accuracy and speed at significant scale.” This multi-year agreement between Pace and Prudential’s ILI business began as a pilot and quickly moved to full production after demonstrating clear improvements in speed and operati
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release
OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly
Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release
Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit
Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release
New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc
LTIMindtree Wins Two 2025 AWS Partner Awards at AWS re:Invent4.12.2025 13:45:00 CET | Press release
Recognized as Application Modernization Consulting Partner of the Year and Industry Partner of the Year - Travel and Hospitality winner LTIMindtree [NSE: LTIM, BSE: 540005], a leading global technology consulting and digital solutions provider, announced that it received the AWS 2025 Geography and Global Partner Awards, recognizing leaders around the globe who play key roles in helping clients drive innovation and build solutions on Amazon Web Services (AWS). LTIMindtree has been awarded Application Modernization Consulting Partner of the Year (Global) and Industry Partner of the Year - Travel and Hospitality. At the AWS re:Invent 2025 Partner Awards Gala, partners were recognized for their specialization, innovation, and collaboration, and for evolving business models that enable success on AWS while supporting their customers. LTIMindtree was recognized as: The Industry Partner of the Year - Travel and Hospitality: Recognized as a trusted transformation partner in Travel and Hospital
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
